The present invention provides a liquid aqueous formulation for the intranasaladministration of apomorphine, which comprises: (a) at least about 15 mg/mlof apomorphine； and (b) a solubilising agent selected from (i) at least one polyoxyethylene-polyoxypropylenecopolymer (poloxamer)； (ii) at least one cyclodextrin； and (iii) at least onecyclodextrin together with chitosan. The formulations of the invention canbe used in the treatment/management of Parkinson's disease.
